Barclays
MBII

Barclays’s Marrone Bio Innovations, Inc. MBII Stock Holding History

Barclays’s Portfolio MBII Stock Details MBII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,439
Closed -$18K – 5477
2022
Q1 		$18K Sell
16,439
-147,032
-90% -$111K ﹤0.01% 4478
2021
Q4 		$117K Buy
163,471
+81,958
+101% +$66.3K ﹤0.01% 3695
2021
Q3 		$74K Buy
81,513
+25,075
+44% +$30.2K ﹤0.01% 4012
2021
Q2 		$93K Sell
56,438
-28,411
-33% -$47.5K ﹤0.01% 3871
2021
Q1 		$177K Buy
84,849
+62,462
+279% +$130K ﹤0.01% 3768
2020
Q4 		$28K Sell
22,387
-7,717
-26% -$9.21K ﹤0.01% 4614
2020
Q3 		$37K Sell
30,104
-6,142
-17% -$7.47K ﹤0.01% 4736
2020
Q2 		$43K Buy
36,246
+19,021
+110% +$17.6K ﹤0.01% 4996
2020
Q1 		$14K Sell
17,225
-34,647
-67% -$36.7K ﹤0.01% 5739
2019
Q4 		$52K Buy
51,872
+26,297
+103% +$31.9K ﹤0.01% 5730
2019
Q3 		$36K Sell
25,575
-8,058
-24% -$11.4K ﹤0.01% 6052
2019
Q2 		$50K Buy
33,633
+18,215
+118% +$28.2K ﹤0.01% 6101
2019
Q1 		$24K Buy
+15,418
New +$23.5K ﹤0.01% 6287
2018
Q4 		– Sell
-20,451
Closed -$37K – 7522
2018
Q3 		$37K Buy
20,451
+16,447
+411% +$31.9K ﹤0.01% 6237
2018
Q2 		$7K Sell
4,004
-16,196
-80% -$30.1K ﹤0.01% 6651
2018
Q1 		$40K Buy
+20,200
New +$27.1K ﹤0.01% 6061
2015
Q4 		– Sell
-900
Closed -$2K – 6772
2015
Q3 		$2K Buy
+900
New +$1.75K ﹤0.01% 6408
2015
Q2 		– Sell
-1,012
Closed -$4K – 7284
2015
Q1 		$4K Buy
1,012
+219
+28% +$811 ﹤0.01% 6719
2014
Q4 		$2K Sell
793
-9,683
-92% -$25.6K ﹤0.01% 7139
2014
Q3 		$21K Buy
10,476
+9,823
+1,504% +$65.7K ﹤0.01% 6462
2014
Q2 		$7K Buy
653
+436
+201% +$4.94K ﹤0.01% 7017
2014
Q1 		$3K Buy
217
+68
+46% +$1.07K ﹤0.01% 7353
2013
Q4 		$3K Sell
149
-122
-45% -$1.98K ﹤0.01% 7294
2013
Q3 		$4K Buy
+271
New +$3.8K ﹤0.01% 7059

Other funds holding MBII

AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
EFI
EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return

Barclays's MBII Position: Q2 2022 in Review

Barclays sold out of Marrone Bio Innovations, Inc. (MBII) in Q2 2022, closing a stake of 16,439 shares — an estimated $18K sold.

Barclays first reported a position in MBII in Q3 2013 and held it in 24 quarters. The position peaked at $177K in Q1 2021. 62 funds tracked by Wall St. Rank hold MBII as of Q2 2022.

  • Barclays reported no remaining Marrone Bio Innovations, Inc. position as of Q2 2022 after selling out during the quarter.
  • Barclays sold 16,439 Marrone Bio Innovations, Inc. shares in Q2 2022, an estimated $18K.
  • Barclays first reported a position in Marrone Bio Innovations, Inc. in Q3 2013 and held it in 24 quarters.
  • Barclays's Marrone Bio Innovations, Inc. position peaked at $177K in Q1 2021.
  • 62 funds tracked by Wall St. Rank held Marrone Bio Innovations, Inc. as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.